ArticleJournal of global health2026
The economic burden of respiratory syncytial virus and other acute respiratory infections among children <2 years old seeking care at a tertiary facility in Accra, Ghana.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global burden of the respiratory syncytial virus (RSV) disproportionately affects low- and middle-income countries (LMICs). The World Health Organization's Strategic Advisory Group of Experts on Immunisation recently recommended the global implementation of emerging RSV immunisation strategies to protect infants. Cost of illness data are needed to estimate the economic burden of RSV and evaluate the introduction of these immunisation strategies in LMICs. Here, we estimated RSV-associated costs in Ghana. Methods: We measured resource utilisation from the societal, health system, and household perspectives for children <2 years old receiving care for (severe) acute respiratory infections at Africa's third largest referral centre located in Accra, Ghana. During the 2023 respiratory season, children were tested for RSV using molecular point-of-care testing at inpatient and outpatient facilities. Direct medical, direct non-medical, and indirect cost data were collected via questionnaire-based caregiver interviews and gathered from hospital records. Interviews took place at the index visit, upon discharge, and during follow-up (four-six weeks post discharge). Results: Of 128 participating children, 59 (46%) and 69 (54%) received care at outpatient and inpatient facilities, respectively. RSV was detected in 58 (45%) children. From a societal perspective, the average cost per episode of RSV infection was USD 69 (95% confidence interval (CI) = 60-77) for outpatients and USD 488 (95% CI = 374-601) for inpatients. We estimated health system costs exceeding USD 30 and USD 200 on average for outpatient and inpatient care, respectively. Out-of-pocket costs borne by households were USD 32, (95% CI = 24-40) for outpatient care and USD 213 (95% CI = 158-269) for inpatient care. Household costs associated with RSV were equivalent to 88% (outpatients) and 592% (inpatients) of the Ghanaian monthly minimum wage in 2023. Conclusions: In this urban tertiary setting, we found a significant economic burden of medically attended RSV, carried by the Ghanaian health system and households. Our findings will be valuable to stakeholders in evaluating emerging interventions for RSV prevention in Ghana and comparable countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.